April 25, 2007 - Alpharma Inc., a global specialty pharmaceutical company, announced that it has received FDA clearance for the KADIAN 10mg strength capsule. The company expects to launch this new dosage strength in 2007.
This is the second FDA approval for a KADIAN line extension in 2007. In March, the company received FDA approval for a 200mg dosage strength which was launched in April 2007. KADIAN is Alpharma's branded extended release morphine sulfate product and is currently marketed in 20mg, 30mg, 50mg, 60mg, 80mg, 100mg and 200mg dosage strengths.
KADIAN's wide range of dosage strengths is intended to assist in physicians' efforts to individualize their patient's treatments by offering more choices in managing their pain.
KADIAN (morphine sulfate extended-release) Capsules are an extended- release formulation of morphine sulfate indicated for the management of moderate-to-severe chronic pain, when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Capsules can be taken once-daily (q24h) or twice-daily (q12h), as prescribed, to provide up to 24 hours of pain relief. The 100 mg and 200 mg capsules are for use in opioid-tolerant patients only. KADIAN offers flexible dosing and administration options that allow physicians to fine tune titration schedules and tailor treatment for individual patient needs.
For more information visit www.KADIAN.com.